Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 337

Results For "IMI"

3550 News Found

Wipro GE Healthcare introduces remote monitoring solution for COVID 19
Healthcare | August 04, 2021

Wipro GE Healthcare introduces remote monitoring solution for COVID 19

Apollo hospital-Hyderabad, Kainos Hospital-Rohtak and Apex Hospital Jaipur have deployed this solution


Evexia Lifecare to manufacture API of Isometa
News | August 03, 2021

Evexia Lifecare to manufacture API of Isometa

Robust demand for the product across the Middle East, Africa and Latin America


Morepen Laboratories posts Q1FY22 consolidated PAT of Rs. 30.47 Cr
News | August 03, 2021

Morepen Laboratories posts Q1FY22 consolidated PAT of Rs. 30.47 Cr

The company posted net profit of Rs.19.36 crores for the period ended June 30, 2020.


API exports surpass imports by value in 2020-21
Policy | August 03, 2021

API exports surpass imports by value in 2020-21

The govt has rolled out three schemes for promoting the manufacture of API


Drug exports grow on the back of govt support
Policy | August 03, 2021

Drug exports grow on the back of govt support

Drug formulations and biologics make impressive gains


PI Industries acquires API business of Ind Swift Laboratories
News | August 02, 2021

PI Industries acquires API business of Ind Swift Laboratories

Turnover of API division of ISLL stood at Rs 856.58 crore


Granules India Q1FY22 consolidated net profit at Rs. 120.20 Cr
News | July 28, 2021

Granules India Q1FY22 consolidated net profit at Rs. 120.20 Cr

The company posted net profit of Rs.111.44 crores for the period ended June 30, 2020.


Morepen Laboratories posts Q1FY22 consolidated PAT of Rs. 30.47 Cr
News | July 28, 2021

Morepen Laboratories posts Q1FY22 consolidated PAT of Rs. 30.47 Cr

The company posted net profit of Rs.19.36 crores for the period ended June 30, 2020.


Morepen to start Sputnik V Vaccine commercial production in 4-6 weeks
News | July 28, 2021

Morepen to start Sputnik V Vaccine commercial production in 4-6 weeks

The first six batches are being shipped to the Gamaleya Center, Moscow for the quality approval


GlaxoSmithKline delivers 19% revenue growth for Q1 FY22
News | July 27, 2021

GlaxoSmithKline delivers 19% revenue growth for Q1 FY22

The company has decided to transfer our rights in relation to the lodex and Ostocalcium brands to GlaxoSmithKline Asia Private Limited